New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case–control MISSIL study
Jean-Guillaume Letarouilly
,
Thao Pham
,
Adeline Pierache
(1)
,
Émilie Acquacalda
,
Béatrice Banneville
,
Sébastien Barbarot
(2)
,
Pauline Baudart
,
Élodie Bauer
,
Pascal Claudepierre
,
Arnaud Constantin
,
Emmanuelle Dernis
,
Renaud Felten
,
Philippe Gaudin
,
Céline Girard
(3)
,
Bruno Gombert
,
Philippe Goupille
,
Xavier Guennoc
,
Isabelle Henry-Desailly
,
Denis Jullien
,
Elena Karimova
,
Sylvain Lanot
,
Loïc Le Dantec
,
Tristan Pascart
(4)
,
Laurianne Plastaras
,
Nathalie Sultan
,
Xavier Truchet
,
Stéphane Varin
,
Daniel Wendling
,
Louise Gaboriau
,
Delphine Staumont-Sallé
(5)
,
Laurent Peyrin-Biroulet
(6)
,
René-Marc Flipo
1
METRICS -
Evaluation des technologies de santé et des pratiques médicales - ULR 2694
2 PhAN - Physiopathologie des Adaptations Nutritionnelles
3 PCCEI - Pathogenesis and Control of Chronic and Emerging Infections
4 MABLab - Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490
5 INFINITE - Institute for Translational Research in Inflammation - U 1286
6 Service d'Hépato-gastro-entérologie [CHRU Nancy]
2 PhAN - Physiopathologie des Adaptations Nutritionnelles
3 PCCEI - Pathogenesis and Control of Chronic and Emerging Infections
4 MABLab - Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490
5 INFINITE - Institute for Translational Research in Inflammation - U 1286
6 Service d'Hépato-gastro-entérologie [CHRU Nancy]
Jean-Guillaume Letarouilly
- Fonction : Auteur
- PersonId : 806270
- ORCID : 0000-0003-2793-6303
- IdRef : 197737102
Thao Pham
- Fonction : Auteur
Émilie Acquacalda
- Fonction : Auteur
Béatrice Banneville
- Fonction : Auteur
Pauline Baudart
- Fonction : Auteur
Élodie Bauer
- Fonction : Auteur
Pascal Claudepierre
- Fonction : Auteur
Arnaud Constantin
- Fonction : Auteur
Emmanuelle Dernis
- Fonction : Auteur
Renaud Felten
- Fonction : Auteur
- PersonId : 1184648
- ORCID : 0000-0002-4951-4032
Philippe Gaudin
- Fonction : Auteur
Bruno Gombert
- Fonction : Auteur
Philippe Goupille
- Fonction : Auteur
Xavier Guennoc
- Fonction : Auteur
Isabelle Henry-Desailly
- Fonction : Auteur
Denis Jullien
- Fonction : Auteur
Elena Karimova
- Fonction : Auteur
Sylvain Lanot
- Fonction : Auteur
Loïc Le Dantec
- Fonction : Auteur
Laurianne Plastaras
- Fonction : Auteur
Nathalie Sultan
- Fonction : Auteur
Xavier Truchet
- Fonction : Auteur
Stéphane Varin
- Fonction : Auteur
Daniel Wendling
- Fonction : Auteur
- PersonId : 759310
- ORCID : 0000-0002-4687-5780
Louise Gaboriau
- Fonction : Auteur
René-Marc Flipo
- Fonction : Auteur
Résumé
Objectives To describe new-onset IBD (new IBD) in patients treated with IL-17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life. Methods A French national registry (MISSIL) aimed to report all cases of new IBD in patients treated with IL-17i from January 2016 to December 2019. Using the estimated number of patients treated by IL-17 in France during the study period, the annual incidence rates of new IBD was reported in IL-17i-treated patients. A case–control study was performed with two controls per new IBD case matched by gender, age and underlying inflammatory disease. Results Thirty-one cases of new IBD under IL-17i were collected: 27 patients treated for spondyloarthritis and four patients for psoriasis. All were observed with secukinumab (SEK). The median time to onset of new IBD symptoms was 4.0 (1.5–7.5) months. SEK was discontinued in all patients. The evolution was favourable with complete resolution (17/31), improvement (7/31) or stabilization (5/31). Two patients died: one due to a massive myocardial infarction and one due to post-colectomy complications. The incidence of new IBD decreased from 0.69/100 patient-years [PY] (7/1010) in 2016 to 0.08/100 PY (6/7951) in 2019. No previous treatment with etanercept (odds ratio [OR] = 0.33, 95% CI: 0.14–0.80, P = 0.014) and low number of previous biologic therapies (OR = 0.67, 95% CI: 0.47, 0.94, P = 0.021) were significantly associated with new IBD. Conclusion The incidence of new IBD was low and decreased from 2016 to 2019. The outcome was favourable in 24 out of 31 patients, but two patients died.
Format du dépôt | Notice |
---|---|
Type de dépôt | Article dans une revue |
Résumé |
en
Objectives To describe new-onset IBD (new IBD) in patients treated with IL-17 inhibitors (IL-17i), to assess their incidence and to identify their risk factors in real life. Methods A French national registry (MISSIL) aimed to report all cases of new IBD in patients treated with IL-17i from January 2016 to December 2019. Using the estimated number of patients treated by IL-17 in France during the study period, the annual incidence rates of new IBD was reported in IL-17i-treated patients. A case–control study was performed with two controls per new IBD case matched by gender, age and underlying inflammatory disease. Results Thirty-one cases of new IBD under IL-17i were collected: 27 patients treated for spondyloarthritis and four patients for psoriasis. All were observed with secukinumab (SEK). The median time to onset of new IBD symptoms was 4.0 (1.5–7.5) months. SEK was discontinued in all patients. The evolution was favourable with complete resolution (17/31), improvement (7/31) or stabilization (5/31). Two patients died: one due to a massive myocardial infarction and one due to post-colectomy complications. The incidence of new IBD decreased from 0.69/100 patient-years [PY] (7/1010) in 2016 to 0.08/100 PY (6/7951) in 2019. No previous treatment with etanercept (odds ratio [OR] = 0.33, 95% CI: 0.14–0.80, P = 0.014) and low number of previous biologic therapies (OR = 0.67, 95% CI: 0.47, 0.94, P = 0.021) were significantly associated with new IBD. Conclusion The incidence of new IBD was low and decreased from 2016 to 2019. The outcome was favourable in 24 out of 31 patients, but two patients died.
|
Titre |
en
New-onset inflammatory bowel diseases among IL-17 inhibitor-treated patients: results from the case–control MISSIL study
|
Auteur(s) |
Jean-Guillaume Letarouilly
, Thao Pham
, Adeline Pierache
1
, Émilie Acquacalda
, Béatrice Banneville
, Sébastien Barbarot
2
, Pauline Baudart
, Élodie Bauer
, Pascal Claudepierre
, Arnaud Constantin
, Emmanuelle Dernis
, Renaud Felten
, Philippe Gaudin
, Céline Girard
3
, Bruno Gombert
, Philippe Goupille
, Xavier Guennoc
, Isabelle Henry-Desailly
, Denis Jullien
, Elena Karimova
, Sylvain Lanot
, Loïc Le Dantec
, Tristan Pascart
4
, Laurianne Plastaras
, Nathalie Sultan
, Xavier Truchet
, Stéphane Varin
, Daniel Wendling
, Louise Gaboriau
, Delphine Staumont-Sallé
5
, Laurent Peyrin-Biroulet
6
, René-Marc Flipo
1
METRICS -
Evaluation des technologies de santé et des pratiques médicales - ULR 2694
( 221576 )
- 1, place de Verdun 59045 - Lille cedex
- France
2
PhAN -
Physiopathologie des Adaptations Nutritionnelles
( 1088525 )
- 1 place Alexis Ricordeau 44093 Nantes Cedex 1 France
- France
3
PCCEI -
Pathogenesis and Control of Chronic and Emerging Infections
( 1100798 )
- INSERM
60 Rue de Navacelles
CS 34493
34394 Montpellier cedex 5 France
- France
4
MABLab -
Marrow Adiposity & Bone Lab - Adiposité Médullaire et Os - ULR 4490
( 201443 )
- Université du Littoral-Côte d’Opale - Boulevard Bassin Napoléon – Quai Masset- Bâtiment B -- 62200 Boulogne sur Mer -
(ex-Pmoi : Université Lille 2 - Faculté de chirurgie dentaire
- Place de Verdun
- F 59000 Lille)
- France
5
INFINITE -
Institute for Translational Research in Inflammation - U 1286
( 1031145 )
- Infinite (Ex-Liric) - Faculté de Médecine - Pôle Recherche, 4ème étage - 1 place de Verdun - 59045 LILLE CEDEX
- France
6
Service d'Hépato-gastro-entérologie [CHRU Nancy]
( 487464 )
- Vandoeuvre-les-Nancy
- France
|
Page/Identifiant |
p.2848-2855
|
Public visé |
Scientifique
|
Vulgarisation |
Non
|
Comité de lecture |
Oui
|
Audience |
Internationale
|
Langue du document |
Anglais
|
Nom de la revue |
|
Date de publication |
2022-07-01
|
Volume |
61
|
Numéro |
7
|
Domaine(s) |
|
Mots-clés |
en
IBD, IL-17 inhibitor, PsA, psoriasis, real-world, secukinumab, spondyloarthritis
|
DOI | 10.1093/rheumatology/keab819 |
Pubmed Id | 34730790 |
Loading...